TY - JOUR
T1 - Cystic fibrosis mutation analysis: Report from 22 U.K. regional genetics laboratories
AU - Schwarz, Martin J.
AU - Malone, Geraldine
AU - Haworth, Andrea
AU - Cheadle, Jeremy P.
AU - Meredith, A. Linda
AU - Gardner, Anne
AU - Sawyer, I. Hilary
AU - Connarty, Margaret
AU - Dennis, Nick
AU - Seller, Anneke
AU - Harris, Ann
AU - Taylor, Rohan
AU - Dear, Simon
AU - Middleton-Price, Helen
AU - McMahon, Cathie
AU - Mayall, Ed
AU - McMahon, R
AU - Barton, David E.
AU - Giles, Martin
AU - Lindley, Victoria
AU - Plaha, Davinder S.
AU - Price, Susan
AU - Sharif, Abid
AU - Cross, Gareth S.
AU - Dalton, Ann
AU - Taylor, Graham
AU - Wallace, Andrew
AU - Tassabehji, Mayada
AU - Whittaker, Joanne L.
AU - Butler, Rachel
AU - Curtis, Ann
AU - Pinkett, Ros
AU - Gilfillan, Annette J.
AU - Brock, David J. H.
AU - Higgins, G. Scott
AU - Lanyon, George
AU - Miedzybrodzka, Zosia
AU - Davidson, Mark
AU - Graham, Colin A.
AU - Hill, Alison J. M.
N1 - Schwarz, M. J., Malone, G., Haworth, A., Cheadle, J. P., Meredith, A. L., Gardner, A., Sawyer, I. H., Connarty, M., Dennis, N., Seller, A., Harris, A., Taylor, R., Dear, S., Middleton-Price, H., McMahon, C., Mayall, E., McMahon, R., Barton, D. E., Giles, M., Lindley, V., Plaha, D. S., Price, S., Sharif, A., Cross, G. S., Dalton, A., Taylor, G., Wallace, A., Tassabehji, M., Whittaker, J. L., Butler, R., Curtis, A., Pinkett, R., Gilfillan, A. J., Brock, D. J. H., Higgins, G. S., Lanyon, G., Miedzybrodzka, Z., Davidson, M., Graham, C. A. Hill, A. J. M. Cystic fibrosis mutation analysis: Report from 22 U.K. regional genetics laboratories. Human Mutation, 6 (4), 326-333
PY - 1995
Y1 - 1995
N2 - We have collated the results of cystic fibrosis (CF) mutation analysis conducted in 22 laboratories in the United Kingdom. A total of 9,807 CF chromosomes have been analysed, demonstrating 56 different mutations so far observed and accounting for 86% of CF genes in the native Caucasian population of the United Kingdom. ΔF508 is the most common at 753% of CF mutations (range 56.5–83.7%), followed by G551D (3.08%; range 0.71–7.60%), G542X (1.68%; range 0.85–3.66%), 621 + 1 (G>T) (0.93%; range 0.41–3.16%), 1717‐1(G>A) (0.57%; range 0.17‐1.14%), 1898+ 1)(G>A) (0.46%), R117H (0.46%), N1303K (0.46%), and R553X (0.46%). The data show a clear geographical variation in the distribution of some of the mutations, most notably a marked regional variation in the distribution of 621 + 1 (G>T)and 1989+ 1(G>A), which are both apparently more frequent in Wales. R560T and R117H appear to be more frequent in Ireland and Scotland, and G551D more frequent in Scotland. In summary, these data illustrate that the mutations present within a particular population need to be defined in order to provide meaningful carrier screening and testing for rare mutations in affected individuals. Furthermore, it is apparent that the ethnic origin of a patient, even within a small country such as the United Kingdom, should be taken into account. © 1995 Wiley‐Liss, Inc.
AB - We have collated the results of cystic fibrosis (CF) mutation analysis conducted in 22 laboratories in the United Kingdom. A total of 9,807 CF chromosomes have been analysed, demonstrating 56 different mutations so far observed and accounting for 86% of CF genes in the native Caucasian population of the United Kingdom. ΔF508 is the most common at 753% of CF mutations (range 56.5–83.7%), followed by G551D (3.08%; range 0.71–7.60%), G542X (1.68%; range 0.85–3.66%), 621 + 1 (G>T) (0.93%; range 0.41–3.16%), 1717‐1(G>A) (0.57%; range 0.17‐1.14%), 1898+ 1)(G>A) (0.46%), R117H (0.46%), N1303K (0.46%), and R553X (0.46%). The data show a clear geographical variation in the distribution of some of the mutations, most notably a marked regional variation in the distribution of 621 + 1 (G>T)and 1989+ 1(G>A), which are both apparently more frequent in Wales. R560T and R117H appear to be more frequent in Ireland and Scotland, and G551D more frequent in Scotland. In summary, these data illustrate that the mutations present within a particular population need to be defined in order to provide meaningful carrier screening and testing for rare mutations in affected individuals. Furthermore, it is apparent that the ethnic origin of a patient, even within a small country such as the United Kingdom, should be taken into account. © 1995 Wiley‐Liss, Inc.
KW - CYSTIC FIBROSIS
KW - GEOGRAPHICAL VARIATION
KW - MUTATIONS
KW - REGULATOR CFTR GENE
KW - NUCLEOTIDE-BINDING FOLD
KW - MOLECULAR CHARACTERIZATION
KW - NONSENSE MUTATION
KW - IDENTIFICATION
KW - POPULATION
KW - CHROMOSOMES
KW - COMMON
KW - Mutations
KW - Cystic fibrosis
KW - Geographical variation
UR - http://www.scopus.com/inward/record.url?scp=0028784242&partnerID=8YFLogxK
U2 - 10.1002/humu.1380060406
DO - 10.1002/humu.1380060406
M3 - Article
SN - 1059-7794
VL - 6
SP - 326
EP - 333
JO - Human Mutation
JF - Human Mutation
IS - 4
ER -